SG11201903012RA - Anti-c1s antibodies and methods of use thereof - Google Patents
Anti-c1s antibodies and methods of use thereofInfo
- Publication number
- SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- present disclosure
- disclosure provides
- san francisco
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407390P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056349 WO2018071676A1 (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903012RA true SG11201903012RA (en) | 2019-05-30 |
Family
ID=61906346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903012RA SG11201903012RA (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20200048332A1 (es) |
| EP (1) | EP3525583A4 (es) |
| JP (3) | JP7069138B2 (es) |
| KR (2) | KR102638884B1 (es) |
| CN (2) | CN110300520B (es) |
| AR (1) | AR110677A1 (es) |
| AU (2) | AU2017341766A1 (es) |
| BR (1) | BR112019007309A2 (es) |
| CA (1) | CA3040253A1 (es) |
| CL (1) | CL2019000975A1 (es) |
| CO (1) | CO2019004741A2 (es) |
| CR (1) | CR20190223A (es) |
| DO (1) | DOP2019000085A (es) |
| EA (1) | EA201990884A1 (es) |
| EC (1) | ECSP19033211A (es) |
| IL (2) | IL265957B2 (es) |
| MX (1) | MX2019004259A (es) |
| PE (1) | PE20191031A1 (es) |
| PH (1) | PH12019500789A1 (es) |
| SG (1) | SG11201903012RA (es) |
| TN (1) | TN2019000109A1 (es) |
| TW (2) | TWI773695B (es) |
| WO (1) | WO2018071676A1 (es) |
| ZA (1) | ZA201902247B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| US8945562B2 (en) | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
| LT3280440T (lt) | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai |
| JP2021502967A (ja) | 2017-11-14 | 2021-02-04 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体および使用方法 |
| CN115702165A (zh) * | 2020-04-20 | 2023-02-14 | 建新公司 | 人源化抗补体因子Bb抗体及其用途 |
| CA3187866A1 (en) * | 2020-08-06 | 2022-02-10 | Jaime Morales ARIAS | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| CN117642431A (zh) * | 2021-07-13 | 2024-03-01 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| WO2023287573A2 (en) | 2021-07-13 | 2023-01-19 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| US20240025978A1 (en) | 2022-06-24 | 2024-01-25 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0905253A3 (en) | 1992-12-03 | 2000-11-02 | Genzyme Corporation | Adenoviral vector deleted of all E4-ORF except ORF6 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| ATE314482T1 (de) | 1993-10-25 | 2006-01-15 | Canji Inc | Rekombinante adenoviren-vektor und verfahren zur verwendung |
| WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| DE69703974T2 (de) | 1996-10-17 | 2001-07-19 | Oxford Biomedica (Uk) Ltd., Oxford | Retrovirale vektoren |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| AU2002360355B2 (en) | 2001-11-09 | 2005-07-07 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| US9715692B1 (en) | 2003-04-11 | 2017-07-25 | Facebook, Inc. | System for managing bids for pay-per-click search engines |
| EP1697741A4 (en) * | 2003-12-04 | 2008-02-13 | Xencor Inc | PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF |
| RU2368622C2 (ru) * | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Антитела к р-селектину |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101218295B (zh) | 2005-07-05 | 2010-12-08 | 株式会社钟化 | 甲基丙烯酸类树脂组合物 |
| FR2897868B1 (fr) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
| EP3705577A1 (en) | 2006-06-21 | 2020-09-09 | uniQure IP B.V. | Aav vectors with improved rep coding sequences for production in insect cells |
| WO2009020640A2 (en) * | 2007-08-08 | 2009-02-12 | Swarmcast, Inc. | Media player plug-in installation techniques |
| WO2010063785A2 (en) | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2826860B1 (en) | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| WO2014066744A2 (en) * | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| US8945562B2 (en) | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
| AU2014213147B2 (en) * | 2013-01-31 | 2019-01-17 | lmmunAbs Inc. | C5 antibody and method for preventing and treating complement-related diseases |
| WO2014189378A1 (en) | 2013-05-23 | 2014-11-27 | Broteio Pharma B.V. | Binding molecules that bind human complement factor c2 and uses thereof |
| MY175896A (en) * | 2013-07-09 | 2020-07-14 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| LT3280440T (lt) * | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai |
-
2017
- 2017-10-12 PE PE2019000814A patent/PE20191031A1/es unknown
- 2017-10-12 WO PCT/US2017/056349 patent/WO2018071676A1/en unknown
- 2017-10-12 CN CN201780074920.XA patent/CN110300520B/zh active Active
- 2017-10-12 EA EA201990884A patent/EA201990884A1/ru unknown
- 2017-10-12 IL IL265957A patent/IL265957B2/en unknown
- 2017-10-12 TW TW106134895A patent/TWI773695B/zh active
- 2017-10-12 AU AU2017341766A patent/AU2017341766A1/en not_active Abandoned
- 2017-10-12 CA CA3040253A patent/CA3040253A1/en active Pending
- 2017-10-12 BR BR112019007309A patent/BR112019007309A2/pt unknown
- 2017-10-12 MX MX2019004259A patent/MX2019004259A/es unknown
- 2017-10-12 CR CR20190223A patent/CR20190223A/es unknown
- 2017-10-12 TN TNP/2019/000109A patent/TN2019000109A1/en unknown
- 2017-10-12 TW TW111130089A patent/TWI846007B/zh active
- 2017-10-12 AR ARP170102855A patent/AR110677A1/es unknown
- 2017-10-12 EP EP17859451.1A patent/EP3525583A4/en active Pending
- 2017-10-12 KR KR1020197013448A patent/KR102638884B1/ko active IP Right Grant
- 2017-10-12 KR KR1020247005368A patent/KR20240025715A/ko active Application Filing
- 2017-10-12 IL IL308156A patent/IL308156A/en unknown
- 2017-10-12 CN CN202211195613.6A patent/CN116554320A/zh active Pending
- 2017-10-12 SG SG11201903012RA patent/SG11201903012RA/en unknown
- 2017-10-12 US US16/340,991 patent/US20200048332A1/en not_active Abandoned
- 2017-10-12 JP JP2019519690A patent/JP7069138B2/ja active Active
-
2019
- 2019-04-08 DO DO2019000085A patent/DOP2019000085A/es unknown
- 2019-04-10 ZA ZA2019/02247A patent/ZA201902247B/en unknown
- 2019-04-11 PH PH12019500789A patent/PH12019500789A1/en unknown
- 2019-04-11 CL CL2019000975A patent/CL2019000975A1/es unknown
- 2019-05-08 CO CONC2019/0004741A patent/CO2019004741A2/es unknown
- 2019-05-10 EC ECSENADI201933211A patent/ECSP19033211A/es unknown
-
2022
- 2022-04-28 JP JP2022073972A patent/JP7420864B2/ja active Active
- 2022-07-12 AU AU2022205174A patent/AU2022205174A1/en active Pending
-
2023
- 2023-07-07 US US18/349,027 patent/US20240076363A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002216A patent/JP2024038319A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201908396PA (en) | Methods of treating tumor | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201908918WA (en) | Novel pyridazinone herbicides | |
| SG11201906963QA (en) | Binding agents | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF |